FindTrial
Sign In

Osteoporosis during Menopause

To assess the efficacy of bisphosphonate therapy for preventing bone loss in osteopenic peri-menopausal women

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011964
Enrollment
90
Registered
2018-02-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- OSTEOPENIC PERIMENOPAUSAL AND POST MENOPAUSAL WOMEN

Interventions

Intervention1: zoledronic acid: Nitrogen containing bisphosphonates( zoledronic acid) block the enzyme farnesyl pyrophosphate synthase which is involved in mevalonic acid pathway ,an important path

Sponsors

DEPARTMENT OF ENDOCRINOLOGY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Peri-menopausal women with osteopenia. 2.Post-menopausal women with osteopenia.

Exclusion criteria

Exclusion criteria: 1) Presence of osteoporosis. 2) Presence of celiac disease, 3) Presence of primary hyperparathyroidism, 4) Presence of multiple myeloma 5) Renal or hepatic insufficiency

Design outcomes

Primary

MeasureTime frame
CHANGES IN BONE MINERAL DENSITY AFTER 1 YEARSTimepoint: 1 years—

Secondary

MeasureTime frame
changes in BMDTimepoint: 2 years—

Countries

India

Contacts

Public ContactLAIMAYUM ROMESH SHARMA

PGIMER,CHANDIGARH

ramawalia@rediffmail.com9872997438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026